Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.

By Eric J. Topol, D. Moliterno, H. Herrmann, E. Powers, C. Grines, D. Cohen, E. Cohen, M. Bertrand, Franz‐Josef Neumann, Gregg Stone and 4 more. New England Journal of Medicine, 2001

669 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/d04426d640bd0f9769d633bad8ee77c7a6e31758

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Robert M. Califf
2. Eric J. Topol
3. Joseph S. Alpert
4. Judith Hochman
5. A. Vahanian

In Surgery

1. Robert M. Califf
2. Joseph S. Alpert
3. Judith Hochman

Citations in the corpus

• Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. (2002, background): “Nonetheless, the results of our trial, smaller single-center trials, and those of a recent large comparative trial of GpIIb-IIIa antagonists strongly suggest a complementary role of parenteral GpIIb-IIIa inhibition with dual oral antiplatelet in the setting of PCI, without a concomitant increase in ”
• Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. (2006, background): “There is increasing evidence that treatment with clopidogrel prior to PCI prevents postprocedural ischemic complications(8,9) and may attenuate differences observed between 2 antithrombotic regimens given periinterventionally.(10,11) Several studies have shown that a 600-mg loading dose of clopidogr”
• Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. (2003, background): “Long-term follow-up (6 month and 1 year) is underway in REPLACE-2 to examine the consequencesof adisparity inearly ischemic events, but it is relevant to note that even largerdifferences inearly infarctionrates have not consistently translated into detectable differences in 1-year mortality in other”
• Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. (2002, methodology): “The TARGET study compared two GPIIb/IIIa receptor antagonists, abciximab and tirofiban at the time of PCI in patients with acute coronary syndromes([163]).”
• ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients (2002, methodology): “antagonists, the TARGET trial (Do Tirofiban and ReoPro Give similar Efficacy? Trial) randomized 5,308 patients to tirofiban or abciximab before PCI with the intent to perform stenting (16).”